Quick Answer
Aligos Therapeutics, Inc. reported Cash and Equivalents of $18.30 million for fiscal year 2025.
Aligos Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $18.30M | -50.5% |
| 2024 | $37.00M | -72.7% |
| 2023 | $135.70M | +66.8% |
| 2022 | $81.35M | -56.5% |
| 2021 | $186.82M | -15.2% |
| 2020 | $220.38M | +216.8% |
| 2019 | $69.56M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $41.95M | +18.7% | +124.8% |
| June 30, 2025 | $18.66M | -58.6% | -74.7% |
| March 31, 2025 | $73.76M | +205.4% | +99.4% |
| December 31, 2024 | $37.00M | -72.7% | +4.7% |
| September 30, 2024 | $35.33M | -49.8% | -21.6% |
| June 30, 2024 | $45.08M | -50.4% | +86.7% |
| March 31, 2024 | $24.15M | -69.3% | -82.2% |
| December 31, 2023 | $135.70M | +66.8% | +92.7% |
- Aligos Therapeutics, Inc. showed a decrease of -50.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Aligos Therapeutics, Inc.’s cash and equivalents has declined by 73.7% (from $69.56 million to $18.30 million).
- The most recent figure is from Aligos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: